Status:

TERMINATED

Transcranial Stimulation (tDCS) For the Treatment of Neuropathic Facial Pain

Lead Sponsor:

Beth Israel Medical Center

Conditions:

Facial Pain

Eligibility:

All Genders

21+ years

Phase:

PHASE2

Brief Summary

A study to determine if transcranial direct current stimulation (tDCS, the device that regulates brain activity, can improve pain in people with neuropathic facial pain and compare which modality (inh...

Detailed Description

This is a pilot study designed to collect preliminary data on safety and efficacy of transcranial direct current stimulation (tDCS)to relieve pain in subjects with neuropathic facial pain,and to compa...

Eligibility Criteria

Inclusion

  • Spontaneous facial neuropathic pain due to any of following:
  • Trigeminal neuralgia, type 1, (TN1): facial pain of spontaneous onset with predominantly episodic pain.
  • Trigeminal neuralgia, type 2, (TN2): facial pain of spontaneous onset with predominantly constant pain.
  • Trigeminal neuropathic pain, (TNP): facial pain resulting from unintentional injury to the trigeminal system from facial trauma, oral surgery, ear, nose and throat (ENT) surgery, root injury from posterior fossa or skull base surgery, stroke, etc.
  • Trigeminal deafferentation pain, (TDP): facial pain in a region of trigeminal numbness resulting from intentional injury to the trigeminal system from neurectomy, gangliolysis, rhizotomy, nucleotomy, tractotomy, or other denervating procedures.
  • Symptomatic trigeminal neuralgia, (STN): facial pain resulting from multiple sclerosis.
  • e) Postherpetic neuralgia, (PHN): facial pain resulting from trigeminal Herpes zoster (shingles) outbreak in the trigeminal distribution.
  • Pain intensity score for "worst pain in the last 24 hours" \>4 on a numeric scale 0-10 at the time of enrollment and before the first stimulation of each treatment block.
  • Pain intensity score for "pain right now" \>4 on a numeric scale 0-10 before the first stimulation of each block of treatment.

Exclusion

  • Uncontrolled hypertension, uncontrolled diabetes, uncontrolled cardiovascular disease
  • Other painful conditions than neuropathic facial pain, that are not related to and can't be distinguished from the neuropathic facial pain
  • Pregnancy
  • Implanted neurostimulation devices (e.g. a spinal cord stimulator, a deep brain stimulator, etc)
  • Active illegal drug/alcohol abuse
  • Unable to follow directions or complete tools in English.

Key Trial Info

Start Date :

October 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

21 Patients enrolled

Trial Details

Trial ID

NCT01849796

Start Date

October 1 2010

End Date

December 1 2013

Last Update

December 10 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beth Israel Medical Center

New York, New York, United States, 10033